Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2013
|
| In: |
Journal of cancer research and clinical oncology
Year: 2013, Jahrgang: 139, Heft: 2, Pages: 337-345 |
| ISSN: | 0171-5216 |
| Online-Zugang: |
|
| Verfasserangaben: | Gencer, Deniz ... Hofheinz, Ralf-Dieter |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1631682954 | ||
| 003 | DE-627 | ||
| 005 | 20220815175738.0 | ||
| 007 | tu | ||
| 008 | 130417s2013 xx ||||| 00| ||eng c | ||
| 035 | |a (DE-627)1631682954 | ||
| 035 | |a (DE-576)381236846 | ||
| 035 | |a (DE-599)BSZ381236846 | ||
| 035 | |a (OCoLC)1341053150 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 245 | 0 | 0 | |a Metastatic esophagogastric adenocarcinoma |b trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval |c Gencer, Deniz ... Hofheinz, Ralf-Dieter |
| 264 | 1 | |c 2013 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 700 | 1 | |a Gencer, Deniz |d 1980- |0 (DE-588)140107940 |0 (DE-627)616027850 |0 (DE-576)314627332 |4 oth | |
| 700 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 oth | |
| 773 | 0 | 8 | |i In |t Journal of cancer research and clinical oncology |d Berlin : Springer, 1979 |g 139(2013), 2, Seite 337-345 |w (DE-627)129330493 |w (DE-600)134792-5 |w (DE-576)014586762 |x 0171-5216 |7 nnas |a Metastatic esophagogastric adenocarcinoma trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval |
| 773 | 1 | 8 | |g volume:139 |g year:2013 |g number:2 |g pages:337-345 |g extent:9 |a Metastatic esophagogastric adenocarcinoma trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval |
| 951 | |a AR | ||
| 992 | |a 20130417 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 11 |y j | ||
| 998 | |g 140107940 |a Gencer, Deniz |m 140107940:Gencer, Deniz |d 60000 |d 61200 |e 60000PG140107940 |e 61200PG140107940 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1631682954 |e 3282803397 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Gencer","given":"Deniz","role":"oth","display":"Gencer, Deniz"},{"family":"Hofheinz","given":"Ralf-Dieter","role":"oth","display":"Hofheinz, Ralf-Dieter"}],"title":[{"title_sort":"Metastatic esophagogastric adenocarcinoma","title":"Metastatic esophagogastric adenocarcinoma","subtitle":"trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval"}],"language":["eng"],"name":{"displayForm":["Gencer, Deniz ... Hofheinz, Ralf-Dieter"]},"id":{"eki":["1631682954"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"title":[{"title":"Journal of cancer research and clinical oncology","subtitle":"official organ of the Deutsche Krebsgesellschaft","title_sort":"Journal of cancer research and clinical oncology"}],"part":{"text":"139(2013), 2, Seite 337-345","year":"2013","volume":"139","extent":"9","pages":"337-345","issue":"2"},"language":["ger","eng"],"pubHistory":["93.1979-volume 149, number 20 (December 2023)"],"disp":"Metastatic esophagogastric adenocarcinoma trends in first-line treatment and predictive factors for the implementation of HER2 testing in clinical practice during the first year after trastuzumab market approvalJournal of cancer research and clinical oncology","id":{"eki":["129330493"],"zdb":["134792-5"],"issn":["0171-5216"]},"corporate":[{"display":"Deutsche Krebsgesellschaft","role":"isb"}],"note":["Fortgesetzt als Online-Ausgabe","Ungezählte Beil.: Supplement"],"origin":[{"publisherPlace":"Berlin ; Heidelberg ; New York ; München","dateIssuedKey":"1979","dateIssuedDisp":"1979-[2023]","publisher":"Springer ; Bergmann"}],"recId":"129330493","titleAlt":[{"title":"Cancer research clinical oncology"}],"type":{"bibl":"periodical"}}],"type":{"bibl":"article-journal"},"recId":"1631682954","origin":[{"dateIssuedDisp":"2013","dateIssuedKey":"2013"}]} | ||
| SRT | |a METASTATIC2013 | ||